Kelly Rowe
Family · Las Vegas, NVNPI 1326574328
Payments from drug & device makers
Across 100 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$798
- Novo Nordisk$397
- Biohaven Pharmaceuticals, Inc.$169
- Medtronic$97
- GSK$87
- Lilly USA, LLC$85
- plus $470 from 17 others
What the payments were for
- Food & beverage$2,102100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $798 |
| Novo Nordisk | 13 | $397 |
| Biohaven Pharmaceuticals, Inc. | 9 | $169 |
| Medtronic | 3 | $97 |
| GSK | 4 | $87 |
| Lilly USA, LLC | 5 | $85 |
| Boehringer Ingelheim | 3 | $56 |
| Bayer | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Merck | 2 | $37 |
| Currax Pharmaceuticals LLC | 2 | $34 |
| Novartis | 2 | $33 |
| Acerus Pharmaceuticals Corporation | 1 | $26 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| IBSA Pharma Inc. | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Masimo Corporation | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Intra-sana Laboratories | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$112
How this compares
$2,102 in reported general payments places this provider in the 80th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 30 | $37,981 |
| MounjaroTirzepatide | 16 | $20,704 |
| GlyxambiEmpagliflozin/Linagliptin | 21 | $12,621 |
| XareltoRivaroxaban | 11 | $6,161 |
| Bupropion XlBupropion Hcl | 12 | $824 |
| Gabapentin | 30 | $768 |
| Levothyroxine Sodium | 70 | $699 |
| Ventolin HfaAlbuterol Sulfate | 12 | $674 |
| Tamsulosin Hcl | 39 | $610 |
| Rosuvastatin Calcium | 49 | $564 |
| Atorvastatin Calcium | 58 | $451 |
| Losartan Potassium | 61 | $430 |
| Amlodipine Besylate | 67 | $325 |
| Duloxetine Hcl | 11 | $314 |
| Estradiol | 17 | $311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $397 | $37,98130 claims |
| Lilly USA, LLCMounjaro | $85 | $20,70416 claims |
| Boehringer IngelheimGlyxambi | $56 | $12,62121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Kelly PapeshLas Vegas$44K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.